Interplay between programmed death-ligand 1 and non-coding RNAs

Affiliation
Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences ,Tehran ,Iran
Ghafouri-Fard, Soudeh;
Affiliation
Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences ,Tabriz ,Iran
Shoorei, Hamed;
Affiliation
Department of Pharmacognosy, College of Pharmacy, Hawler Medical University ,Erbil, Kurdistan ,Iraq
Hussen, Bashdar Mahmud;
Affiliation
Faculty of Medicine, Birjand University of Medical Sciences ,Birjand ,Iran
Poornajaf, Yadollah;
Affiliation
Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences ,Tehran ,Iran
Taheri, Mohammad;
Affiliation
Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences ,Tehran ,Iran
Sharifi, Guive

Programmed death-ligand 1 (PD-L1) is a transmembrane protein with essential roles in the suppression of adaptive immune responses. As an immune checkpoint molecule, PD-L1 can be exploited by cancer cells to evade the anti-tumor attacks initiated by the immune system. Thus, blockade of the PD1/PD-L1 axis can eliminate the suppressive signals and release the antitumor immune responses. Identification of the underlying mechanisms of modulation of the activity of the PD1/PD-L1 axis would facilitate the design of more efficacious therapeutic options and better assignment of patients for each option. Recent studies have confirmed the interactions between miRNAs/lncRNAs/circ-RNAs and the PD1/PD-L1 axis. In the current review, we give a summary of interactions between these transcripts and PD-L1 in the context of cancer. We also overview the consequences of these interactions in the determination of the response of patients to anti-cancer drugs.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: Copyright © 2022 Ghafouri-Fard, Shoorei, Hussen, Poornajaf, Taheri and Sharifi

Use and reproduction: